Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Ebola

WHO Clinical Trial Finds New Ebola Vaccine Gives 100 Percent Protec

red-cross-ebolaWashington, DC, December 26, 2016 — Donald G. McNeil Jr. reports that, in a scientific triumph that will change the way the world fights a terrifying killer, an experimental Ebola vaccine tested on humans in the waning days of the West African epidemic has been shown to provide 100 percent protection against the lethal disease.

The vaccine has not yet been approved by any regulatory authority, but it is considered so effective that an emergency stockpile of 300,000 doses has already been created for use should an outbreak flare up again.

Since Ebola was discovered in the former Zaire in 1976, there have been many efforts to create a vaccine. Continue reading

U.S. Health and Human Services Sponsors Commercial Manufacturing Tests for Ebola Vaccine

HHS Logo blueWashington, DC, October 4, 2016 —  An Ebola vaccine will take the next critical steps in development under a $24.75 million contract through May 2020 between the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) and BioProtection Systems Corp. (BPS) of Ames, Iowa.

“The Ebola epidemic of 2014 and 2015 was just the latest outbreak of this potentially deadly disease and we cannot predict when or where the next outbreak will occur,” explained BARDA Acting Director Dr. Richard Hatchett.

“We can prevent future epidemics by acting quickly and decisively to complete development of Ebola vaccines and treatments for use worldwide. As a global public health threat and a potential bioterrorism threat, Ebola remains a priority.” Continue reading

CDC Study Sheds Light on How Some Survive Ebola; Finding Points Way to New Approaches to Treatment

CDC LogoWashington, DC, July 1, 2016 ― A first-of-its-kind Ebola study yields clues to how some people are able to survive the deadly virus and suggests possible avenues for treatments that could save more lives.

Researchers at Centers for Disease Control and Prevention, Emory University School of Medicine, and University of Nebraska Medical Center analyzed the immune responses of Ebola patients treated in the United States.

Their study was recently published online in the Clinical Infectious Disease Journal in the article entitled, “Kinetic Analysis of Biomarkers in a Cohort of U.S. Patients with Ebola Virus Disease.” Continue reading

HHS Advances Development of New Monoclonal Antibody Drug for Ebola

Washington, DC, September 22, 2015 ― A novel Ebola virus disease treatment based on three monoclonal antibodies will advance in development through an agreement between the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) and Regeneron Pharmaceuticals, Inc. of Tarrytown, New York.

ASPR’s Biomedical Advanced Research and Development Authority (BARDA) will provide up to a total of $38 million over the next 23 months to support development as well as manufacturing of the experimental monoclonal antibody therapeutic drug for use in studies. Continue reading

HHS launches National Ebola Training and Education Center

Washington, DC, July 1, 2015 ― To ensure that U.S. health care providers and facilities are prepared to safely identify, isolate, transport, and treat patients with Ebola and other emerging threats, the U.S. Department of Health and Human Services (HHS) today launched a National Ebola Training and Education Center.

A collaborative effort among HHS’s Office of the Assistant Secretary for Preparedness and Response (ASPR), the Centers for Disease Control and Prevention (CDC) and three academic institutions, the program supports further training of health care providers and facilities on strategies to manage Ebola and other emerging infectious diseases. Continue reading

HHS Pursues Fast, Easy Test to Detect Ebola Virus Infections

Washington, DC, June 13, 2015 ― To assist doctors in diagnosing Ebola virus disease quickly, the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) will pursue development of an Ebola virus diagnostic test for use in a doctor’s office, hospital, clinic, or field setting that will provide results within 20 minutes.

“Fast and inexpensive point-of-care diagnostics will improve our ability to control Ebola virus disease outbreaks,” said Robin Robinson, Ph.D., director of ASPR’s Biomedical Advanced Research and Development Authority (BARDA), which will oversee this development program for HHS.  “Faster diagnosis of Ebola virus infections allows for more immediate treatment and an earlier response to protect public health worldwide.” Continue reading

Rapid Ebola Test Is Focus of NIH Grant to Rutgers Scientist

New Brunswick, NJ, December 9, 2014 ― A Rutgers researcher has received a grant of nearly $640,000 from the National Institutes of Health to develop a rapid test to diagnose Ebola as well as other viruses that can cause symptoms similar to Ebola.

David Alland, a professor of medicine and associate dean for clinical research at Rutgers New Jersey Medical School — and the principal investigator for the project — says health workers would be able to take the test to small villages and other remote locations where the spread of Ebola has been especially rampant and diagnose patients where they live. Continue reading

Governor Christie Activates Statewide Ebola Preparedness Plan

Trenton, NJ, October 22, 2014 ― Today, Governor Chris Christie signed Executive Order 164 creating the Ebola Virus Disease Joint Response Team (EVD-JRT) that will direct and coordinate on all matters pertaining to New Jersey’s public health response.

Christie administration officials, state agencies and departments will work in a coordinated manner to ensure the health and safety of New Jersey residents is protected and to execute on decisions in an efficient and effective manner.

The EVD-JRT will also form an advisory panel of additional administration entities, as well as representatives from the medical community. Continue reading

Rutgers Experts Discuss Ebola’s Risk for Americans, Lessons from Medical History

New Brunswick, NJ, August 18, 2014 Rutgers Today’s Rob Forman reports that the outbreak of the deadly Ebola virus in West Africa has Americans concerned about their health and safety.

Rutgers Today asked Rajendra Kapila, an infectious disease physician at Rutgers New Jersey Medical School, and Janet Golden, a medical historian at Rutgers University-Camden, how concerned Americans should be about a potential outbreak in this country.

The World Health Organization (WHO) has declared an international public health emergency in an effort both to contain the spread of the virus, which is considered 90 percent fatal, and to warn people about its seriousness.  A WHO official has said it is likely that the worst of the outbreak is yet to come. Continue reading